Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study

European Journal of Cardio-thoracic Surgery

Volumn 37, Issue 6, 2010, Pages 1427-1432

  Madani, Koroush ^a   Zhao, Ronghua ^a   Lim, Hyun Ja ^a   Casson, Alan G ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Adenocarcinoma; Oesophagus; p53; Survival

Indexed keywords

ADENINE; BIOLOGICAL MARKER; CPG OLIGODEOXYNUCLEOTIDE; CYTOSINE; GENOMIC DNA; GUANINE; PROTEIN P53; THYMINE;

ADULT; AGED; ARTICLE; CARDIA CARCINOMA; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; EXON; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; EPIDEMIOLOGIC METHODS; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952585707     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2009.12.018     Document Type: Article

References (25)

1. Quiros R.M., and Bui C.L. Multidisciplinary approach to esophageal and gastric cancer. Surg Clin North Am 89 (2009) 79-96
2. Lagarde S.M., ten Kate F.J.W., Reitsma J.B., Busch O.R.C., and van Lanschot J.J.B. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 24 (2006) 4347-4355
3. Koppert L.B., Wijnhoven B.P.L., van Dekken H., Tilanus H.W., and Dinjens W.N.M. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 92 (2005) 169-190
4. Fitzgerald R.C. Molecular basis of Barrett's esophagus and oesophageal adenocarcinoma. Gut 55 (2006) 1810-1820
5. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat Med 10 (2004) 789-799
6. Harris S.L., and Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 24 (2005) 2899-2908
7. Sherr C.J. Principles of tumor suppression. Cell 116 (2004) 235-246
8. Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B., and Roth J.A. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 51 (1991) 4495-4499
9. Casson A.G., Tammemagi M., Eskandarian S., Redston M., McLaughlin J., and Ozcelik H. p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. J Clin Pathol: Mol Pathol 51 (1998) 71-79
10. Casson A.G., Evans S.C., Gillis A., Porter G.A., Veuglers P., Darnton S.J., Guernsey D.L., and Hainaut P. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. J Thorac Cardiovasc Surg 125 (2003) 1121-1131
11. Casson A.G., Darnton S.J., Subramanian S., and Hiller L. What is the optimum distal resection margin for esophageal carcinoma?. Ann Thorac Surg 69 (2000) 205-209
12. Casson A.G., Porter G.A., and Veuglers P.J. Evolution and critical appraisal of anastomotic technique following resection of esophageal adenocarcinoma. Dis Esophagus 15 (2002) 296-302
13. Vaninetti N.M., Geldenhuys L., Porter G.A., Risch H., Hainaut P., Guernsey D.L., and Casson A.G. Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Mol Carcinog 47 (2008) 275-285
14. Casson A.G., Madani K., Mann S., Zhao R., Reeder B., and Lim H.J. Does previous fundoplication alter the surgical approach to esophageal adenocarcinoma?. Eur J Cardiothorac Surg 34 (2008) 1097-1102
15. Riberio U., Finkelstein S.D., Safatle-Riberio A.V., Landreneau R.J., Clarke M.R., Bakker A., Swalsky P.A., Gooding W.E., and Posner M.C. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 83 (1998) 7-18
16. Schneider P.M., Stoeltzing O., Roth J.A., Hoelscher A.H., Wegerer S., Mizumoto S., Becker K., Dittler H.J., and Fink U. Siewert JR. p53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Clin Cancer Res 6 (2000) 3153-3158
17. Aloia T.A., Harpole D.H., Reed C.E., Allegra C., Moore M.H., Herndon J.E., and D'Amico T.A. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 72 (2001) 859-866
18. Gibson M.K., Abraham S.C., Wu T.T., Burtness B., Heitmiller R.F., Heath E., and Forastiere A. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemotherapy. Clin Cancer Res 9 (2003) 6461-6468
19. Vijeyasingam R., Darnton S.J., Jenner K., Allen C.A., Billingham C., and Matthews H.R. Expression of p53 protein in oesophageal carcinoma: clinicopathological correlation and prognostic significance. Br J Surg 81 (1994) 1623-1626
20. Sauter E.R., Keller S.M., and Erner S.M. p53 correlates with improved survival in patients with esophageal adenocarcinoma. J Surg Oncol 58 (1995) 269-273
21. Coggi G., Bosari S., Roncalli M., Graziani D., Bossi P., Viale G., Buffa R., Ferrero S., Piazza M., Blandamura S., Segalin A., Bonavina L., and Peracchia A. p53 protein accumulation and p53 mutation in esophageal carcinoma: a molecular and immunohistochemical study with clinicopathologic correlation. Cancer 79 (1997) 425-432
22. INK4A, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 59 (2006) 631-634
23. Rice T.W., Rusch V.W., Apperson-Hansen C., Allen M.S., Chen L.Q., Hunter J.G., Kesler K.A., Law S., Lerut T.E., Reed C.E., Salo J.A., Scott W.J., Swisher S.G., Watson T.J., and Blackstone E.H. Worldwide esophageal cancer collaboration. Dis Esophagus 22 (2009) 1-8
24. Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., Xirodimas D.P., Saville M.K., and Lane D.P. P53 isoforms can regulate p53 transcriptional activity. Genes Dev 19 (2005) 2122-2137
25. Zhao R., and Casson A.G. Epigenetic aberrations and targeted epigenetic therapy of esophageal cancer. Curr Cancer Drug Targets 8 (2008) 509-521